FDA Schedules Critical Peptide Advisory Committee Meetings for July 2026
Key Takeaways
- The FDA will convene its Pharmacy Compounding Advisory Committee on **July 23-24, 2026** to review seven peptides for potential inclusion on the 503A Bulks List
- A second meeting before **February 2027** will evaluate five additional peptides including GHK-Cu, Melanotan II, and Cathelicidin LL-37
- These peptides were removed from FDA’s Category 2 “safety concerns” list on April 15, 2026
- Favorable PCAC votes would trigger formal FDA rulemaking, after which licensed compounding pharmacies could legally prepare these peptides with prescriptions
July Meeting Agenda
On July 23, 2026, the Committee will discuss BPC-157-related bulk drug substances (BPC-157 free base and acetate), KPV-related bulk drug substances (KPV free base and acetate), TB-500-related bulk drug substances (TB-500 free base and acetate), and MOTs-C-related bulk drug substances (MOTs-C free base and acetate).
On July 24, 2026, the Committee will discuss Emideltide (also referred to as delta sleeping inducing peptide/DSIP)-related bulk drug substances, Semax-related substances, and Epitalon.
The specific indications under FDA review include BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-C for obesity and osteoporosis, Emideltide for opioid withdrawal and chronic insomnia, and Semax for cerebral ischemia and trigeminal neuralgia.
Second Meeting Scheduled for Early 2027
The FDA announced the PCAC will convene again before the end of February 2027 to review five additional peptides: Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and Mechano Growth Factor, Pegylated (PEG-MGF).
| July 2026 Meeting | February 2027 Meeting |
|---|---|
| BPC-157 (ulcerative colitis) | Cathelicidin LL-37 (antimicrobial) |
| TB-500 (wound healing) | GHK-Cu (injectable routes) |
| KPV (inflammatory conditions) | Dihexa acetate (cognitive enhancement) |
| MOTS-C (metabolic disorders) | Melanotan II (tanning agent) |
| Emideltide/DSIP (sleep disorders) | PEG-MGF (muscle growth) |
| Semax (neuroprotection) | |
| Epitalon (longevity) |
Regulatory Background
In September 2023, the Biden administration identified a group of peptides with the potential to pose “significant safety risks” and designated them in Category 2, which prohibited compounding pharmacies from making them. The announcement of these advisory committee meetings comes after public remarks by Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. championing the use of peptides during a podcast with Joe Rogan on February 27.
Nothing changes for consumers yet. These peptides cannot be legally compounded until PCAC review is complete and the FDA issues a final determination.
Public Participation Process
The FDA has created a public comment docket (FDA-2025-N-6895) that will remain open until July 22, 2026. Any comments received by July 9 will be presented to the committee. For nominated bulk drug substances, the nominators of these substances will be invited to make a short presentation supporting the nomination.
Industry Implications
Hims & Hers CEO Pat Carroll said “The FDA’s plans to more clearly define the regulatory status of several peptides is an important step toward moving these treatments out of the gray market, and into more trusted channels overseen by vetted healthcare professionals”.
Broader access to compounded peptides could increase demand for therapies that lack rigorous clinical trial data, potentially complicating formulary decisions and reimbursement policies.
Bulk drug substances marketed as “research grade” or “research use only” may present heightened regulatory and quality risk. The outcome is not guaranteed. PCAC voted against five Category 2 peptides in October-December 2024 under the previous administration.
Sources
- FDA – July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- RAPS – FDA considers adding a dozen peptides to its bulk drug compounding list. https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html
- National Law Review – FDA to Convene Pharmacy Compounding Advisory Committee in July. https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding
- Federal Register – Pharmacy Compounding Advisory Committee; Notice of Meeting. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
Last updated: May 18, 2026
Neogenesis BioLabs remains committed to providing research-grade peptides that meet the highest standards of purity and quality for scientific investigation.